Surface Oncology (NASDAQ:SURF) Earns “Buy” Rating from Cowen

Share on StockTwits

Cowen reiterated their buy rating on shares of Surface Oncology (NASDAQ:SURF) in a report published on Wednesday, June 13th.

A number of other research analysts have also commented on the company. Goldman Sachs Group began coverage on Surface Oncology in a report on Monday, May 14th. They set a neutral rating and a $17.00 price target on the stock. Evercore ISI assumed coverage on Surface Oncology in a report on Monday, May 14th. They set an outperform rating and a $26.00 target price on the stock.

Shares of Surface Oncology traded down $0.05, reaching $15.80, during trading hours on Wednesday, according to Marketbeat Ratings. 919 shares of the company’s stock traded hands, compared to its average volume of 192,379. Surface Oncology has a twelve month low of $12.08 and a twelve month high of $17.00.

Surface Oncology (NASDAQ:SURF) last issued its quarterly earnings results on Tuesday, May 29th. The company reported $1.05 EPS for the quarter. The business had revenue of $45.50 million for the quarter.

In other news, major shareholder Lilly Ventures Fund I. Llc bought 266,000 shares of the stock in a transaction that occurred on Monday, April 23rd. The shares were purchased at an average cost of $15.00 per share, with a total value of $3,990,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David S. Grayzel bought 100,000 shares of the stock in a transaction that occurred on Monday, April 23rd. The shares were purchased at an average cost of $15.00 per share, for a total transaction of $1,500,000.00. The disclosure for this purchase can be found here.

Surface Oncology Company Profile

Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company's lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27.

Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply